Pieris Pharmaceuticals, Inc. - Special Call Transcript
(technical difficulty)
Joining me from the Pieris side upfront are Ingmar Bruns, MD, PhD, our Head of Clinical Development; and then 2 seats down, Shane Olwill, PhD, our Head of Translational Science. I'll get to the other colleagues, guest speakers in just a moment.
And I wanted to mention at the outset that Ingmar and Shane will be joining me in introducing our guest speakers. They'll be adding Pieris'-specific content. And also, they'll be facilitating our Q&A in the oncology and respiratory sections. And in the context of this, we may be making forward-looking statements, so I would ask you to consult our disclaimer found on Slide #3.
Pieris is a company that is deploying a single class of next-generation therapeutic proteins that we call Anticalins, and we're deploying them to create 2 different franchises.
On one side, we are constructing and developing bivalent bispecifics with the objective of an agonizing tumor-specific T cells in the tumor microenvironment by agonizing
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |